Videos / Recombinant respiratory syncytial virus pre-fusion F protein vaccine

Product Explainer

Recombinant respiratory syncytial virus pre-fusion F protein vaccine

Description

In this Product Explainer, Infectious Disease Physician and Microbiologist Prof Paul Griffin explains the role of a recombinant respiratory syncytial virus pre-fusion F protein vaccine for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).

Additional resources

NCIRS FAQ: Respiratory syncytial virus (RSV) FAQs | NCIRS.
NCIRS Fact Sheet – state funding of Nirsevimab, eligibility criteria by state: State and territory nirsevimab program summary 2025.pdf

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

Prof Rodney Baber AM

MHT For Women With History or Risk of Cancer

Dr Chris Bollen

Muscle Health in the Elderly

Prof Brendon Yee

GLP-1s For OSA

Dr Andrew Scroop

Oral Corticosteroid Stewardship For Asthma – Why it is Important

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

22 July 2025

expert

Prof Paul Griffin

Infectious Diseases Physician and Clinical Microbiologist; Director of Infectious Diseases, Mater Hospital; Lecturer, University of Queensland

Product Explainer

Recombinant respiratory syncytial virus pre-fusion F protein vaccine